Dominant factor XI deficiency caused by mutations in the factor XI catalytic domain

Blood

Volumn 104, Issue 1, 2004, Pages 128-134

  Kravtsov, Dmitri V ^b   Wu, Wenman ^b   Meijers, Joost C M ^b   Sun, Mao Fu ^b   Blinder, Morey A ^b   Dang, Thao P ^b   Wang, Hongli ^b   Gailani, David ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 11; DIMER; POLYPEPTIDE;

AMINO ACID SUBSTITUTION; ARTICLE; AUTOSOMAL RECESSIVE DISORDER; BLEEDING TENDENCY; CELL LYSATE; CONTROLLED STUDY; DISEASE TRANSMISSION; ENZYME ACTIVE SITE; FIBROBLAST; GENE MUTATION; HEMOPHILIA B; HETEROZYGOSITY; HETEROZYGOTE; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; JEW; PRIORITY JOURNAL;

EID: 3042715266     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-10-3530     Document Type: Article

References (42)

1. Davie E, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance and regulation. Biochemistry. 1991;30:10363-10370.
2. Asakai R, Chung D, Davie E, Seligsohn U. Factor XI deficiency in Ashkenazi Jews in Israel. N Engl J Med. 1991;325:153-158.
3. Seligsohn U. Factor XI deficiency. Thromb Haemost. 1993;70:68-70.
4. Seligsohn U. High gene frequency of factor XI (PTA) deficiency in Ashkenazi Jews. Blood. 1978; 51:1223-1228.
5. Peretz H, Mulai A, Usher S, et al. The two common mutations causing factor XI deficiency in Jews stem from distinct founders: one of ancient Middle Eastern origin and another of more recent European origin. Blood. 1997;90:2654-2659.
6. Rosenthal R, Dreskin O, Rosenthal N. New hemophilia-like disease caused by deficiency of a third plasma thromboplastin factor. Proc Soc Exp Biol Med. 1953;82:171-174.
7. Rosenthal R, Dreskin O, Rosenthal N. Plasma thromboplastin antecedent (PTA) deficiency: clinical, coagulation, therapeutic and hereditary aspects of a new hemophilia-like disease. Blood. 1955;10:120-131.
8. Campbell E, Mednicoff I, Dameshek M. Plasma thromboplastin antecedent (PTA) deficiency. Arch Intern Med. 1957;100:232-240.
9. Cavins J, Wall R. Clinical and laboratory studies of plasma thromboplastin antecedent deficiency (PTA). Am J Med. 1960;29:444-448.
10. Rapaport S, Proctor R, Patch M, Yettra M. The mode of inheritance of PTA deficiency: evidence for the existence of major PTA deficiency and minor PTA deficiency. Blood. 1961;18:149-165.
11. Leiba H, Ramot B, Many R. Heredity and coagulation studies in ten families with factor XI (plasma thromboplastin antecedent) deficiency. Br J Haematol. 1965;11:654-655.
12. Seligsohn U, Griffin, JH. Contact activation and factor XI. In Scriver CR, Beaudet AL, Sly WS, Valle D, eds. Metabolic and Molecular Basis of Inherited Disease. 7th ed. New York NY: McGraw-Hill; 1995:3285-3311.
13. Ragni M, Sinha D, Seaman F, Lewis J, Spero J, Walsh P. Comparison of bleeding tendency, factor XI coagulant activity, and factor Xi antigen in 25 factor XI-deficient kindreds. Blood. 1985;65:719-724.
14. Bolton-Maggs P, Wan-Yin B, McGraw A, Slack J, Kernoff P. Inheritance and bleeding in factor XI deficiency. Br J Haematol. 1988;69:521-528.
15. Martincic D, Zimmerman S, Ware R, Sun M, Whitlock J, Gailani D. Identification of mutations and polymorphisms in the factor Xi genes of an African-American family by dideoxyfingerprinting. Blood. 1998;92:3309-3317.
16. Litz C, Swaim W, Dalmasso A. Factor Xi deficiency: genetic and clinical studies of a single kindred. Am J Hematol. 1988;28:8-12.
17. Saito H, Ratnoff O, Bouma B, Seligsohn U. Failure to detect variant (CRM+) plasma thromboplastin antecedent (factor XI) molecules in hereditary plasma thromboplastin antecedent deficiency: a study of 125 patients of several ethnic backgrounds. J Lab Clin Med. 1985;106:718-722.
18. Fujikawa K, Chung D, Hendrickson L, Davie E. Amino acid sequence of human factor XI, a blood coagulation factor with four tandem repeats that are highly homologous with plasma prekallikrein. Biochemistry. 1986;25:2417-2424.
19. McMullen BA, Fujikawa K, Davie EW. Location of the disulfide bonds in human coagulation factor XI: the presence of tandem apple domains. Biochemistry. 1991;30:2056-2060.
20. Bouma B, Griffin J. Human blood coagulation factor XI, purification, properties, and mechanism of activation by activated factor XII. J Biol Chem. 1977;252:6432-6437.
21. Meijers J, Mulvihill E, Davie E, Chung D. Apple 4 in human blood coagulation factor XI mediates dimer formation. Biochemistry. 1992;31:4680-4684.
22. Meijers J, Davie E, Chung D. Expression of human blood coagulation factor XI: characterization of the defect in factor XI type III deficiency. Blood. 1992;79:1435-1440.
23. Sadler J. Von Willebrand disease. In: Scriver C, Beaudet A, Sly W, et al, eds. Metabolic and Molecular Basis of Inherited Disease. 8th ed. New York, NY: McGraw-Hill; 2001:4415-4431.
24. Chung D, Pratt K, Ichinose A. Disorders of fibrinogen and factor XIII. In: Scriver C, Beaudet A, Sly W, et al, eds. Metabolic and Molecular Basis of Inherited Disease. 8th ed. New York, NY: McGraw-Hill; 2001:4345-4366.
25. Mannhalter C, Hellstern P, Deutsch E. Identification of a defective factor XI cross-reacting material in a factor XI deficient patient. Blood. 1987;70: 31-37.
26. Eikenboom J, Matsushita T, Reitsma P, et al. Dominant type I von Willebrand disease caused by mutated cysteine residues in the D3 domain of von Willebrand factor. Blood. 1996;88:2433-2441.
27. Bodo I, Katsumi A, Tuley E, Eikenboom J, Dong Z, Sadler J. Type I von Willebrand disease mutation Cys1149Arg causes intracellular retention and degradation of heterodimers: a possible mechanism for dominant mutations in oligomeric proteins. Blood. 2001;98:2973-2979.
28. Martincic D, Whitlock J. Improved detection of p53 point mutations by dideoxyfingerprinting (ddF). Oncogene. 1996;13:2039-2044.
29. Sun Y, Gailani D. Identification of a factor IX binding site on the third apple domain of activated factor XI. J Biol Chem. 1996;271:29023-29028.
30. Sun M-F, Zhao M, Gailani D. Identification of amino acids on the factor XI apple 3 domain required for activation of factor IX. J Biol Chem. 1999;274:36373-36378.
31. Todd M, Wright I. Factor XI (PTA) deficiency with no hemorrhagic symptoms. Thromb Diath Haemorrh. 1964;11:186-194.
32. Edson J, White J, Krivit W. The enigma of severe factor XI deficiency without hemorrhagic symptoms. Thromb Diath Haemorrh. 1967;18:342-348.
33. Wehinger H, Klinge O, Alexandrakis E, Schurmann J, Witt J, Seydewitz H. Hereditary hypofibrinogenemia with fibrinogen storage in the liver. Eur J Pediatr. 1983;141:109-112.
34. Duga S, Asselta R, Santagostino E, et al. Missense mutations in the human beta fibrinogen gene cause congenital afibrinogenemia by impairing fibrinogen secretion. Blood. 2000;95: 1336-1341.
35. Brennan S, Wyatt J, Medicina D, Callea F, George P. Fibrinogen brescia: hepatic endoplasmic reticulum storage and hypofibrinogenemia because of a gamma284 Gly→Arg mutation. Am J Pathol. 2000;157:189-196.
36. Brennan S, Maghzal G, Shneider B, Gordon R, Magid M, George P. Novel fibrinogen gamma375 Arg→Trp mutation (fibrinogen aguadilla) causes hepatic endoplasmic reticulum storage and hypofibrinogenemia. Hepatology. 2002;36:652-658.
37. Lamande S, Chessler S, Golub S, et al. Endoplasmic reticulum-mediated quality control of type I collagen production by cells from osteogensis imperfecta patients with mutations in the pro alpha (I) chain carboxyl-terminal propeptide which impair subunit assembly. J Biol Chem. 1995;270: 8642-8649.
38. Bogaert R, Tiller G, Weis M, et al. An amino acid substitution (Gly853→Glu) in the collagen alpha 1 (II) chain produces hypochondrogenesis. J Biol Chem. 1992;267:22522-22526.
39. Asakai R, Chung D, Ratnoff O, Davie E. Factor XI (plasma thromboplastin antecedent) deficiency in Ashkenazi Jews is a bleeding disorder that can result from three types of point mutations. Proc Natl Acad Sci U S A. 1989;86:7667-7671.
40. Cheng Q, Sun M-F, Kravtsov D, Aktimur A, Gailani D. Factor XI apple domains and protein dimerization. J Thromb Haemost. 2003;1:2340-2347.
41. Gailani D, Bolton-Maggs PHB, Blinder M, Butler R, Mountford M, Dang T. Amino acid substitutions in the factor XI catalytic domain associated with factor XI deficiency. Thromb Haemost. 2001; (suppl).
42. Zivelin A, Yatuv R, Livnat S, et al. Severe factor XI deficiency caused by a Gly555Glu substitution encodes for a cross reacting material positive factor XI. Thromb Haemostasis. 2001;(suppl).